Intuitive Surgical, Inc. — Q2 2021 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2021. Intuitive develops and markets the da Vinci surgical system and Ion endoluminal platform, plus related instruments, accessories, and services. Unless stated otherwise, dollar amounts are in millions.
Financial results and liquidity
| Metric | Q2 2021 | Q2 2020 | First half 2021 | First half 2020 |
|---|---|---|---|---|
| Total revenue | $1,464.0 (+72%) | $852.1 | $2,756.1 (+41%) | $1,951.6 |
| Gross profit / margin | $1,023.7 / 69.9% | $502.9 / 59.0% | $1,926.3 / 69.9% | $1,241.1 / 63.6% |
| Operating income / margin | $511.2 / 34.9% | $80.6 / 9.5% | $928.0 / 33.7% | $363.6 / 18.6% |
| Net income attributable to Intuitive | $517.2 | $68.0 | $943.5 | $381.5 |
| Diluted EPS | $4.25 | $0.57 | $7.77 | $3.19 |
- Revenue drivers: Q2 instruments and accessories revenue was $796.4 (+73%), systems revenue $439.6 (+68%), and service revenue $228.0 (+75%). Approximately 408,000 da Vinci procedures were performed, up 68% year over year; 328 da Vinci systems were shipped, up 84%.
- Cash flow: First-half operating cash flow was $1,020.3, versus $582.7 in 2020. Investing cash flow was negative $981.7, principally reflecting investment purchases net of maturities and sales; financing cash flow was negative $43.9.
- Liquidity and debt: Cash, cash equivalents, and investments totaled $7.73 billion at June 30, up about $866 million from year-end 2020. Current assets were $6.02 billion and current liabilities $1.00 billion. The presented balance sheet has no debt line item.
- Other balance-sheet metrics: Total assets were $12.30 billion and total liabilities $1.42 billion. First-half capital spending on property, plant, equipment, and intellectual property was $134.3.
Material changes versus the prior comparable period
- Results rebounded sharply from Q2 2020, when COVID-19 disrupted elective procedures and system purchases. Management attributed 2021 growth to procedure recovery, deferred procedures, system demand, and the larger installed base; therefore, the year-over-year comparison reflects a pandemic-depressed base.
- Q2 da Vinci procedure growth was 77% in the U.S. and 51% outside the U.S. Management reported a 10% year-over-year increase in the installed base, to approximately 6,335 systems, and a 55% increase in utilization versus Q2 2020.
- Q2 systems revenue also benefited from higher placements, operating lease revenue, and lease buyouts; the reported system average selling price declined to approximately $1.55 million from $1.65 million.
- Gross margin improved as production recovered from unusually low Q2 2020 levels and excess/obsolete inventory and freight costs were lower. Prior-year service revenue was reduced by $59 million under the COVID-19 Customer Relief Program.
- Reported tax expense was unusually low: Q2 2021 included a one-time $66.4 million benefit from remeasuring Swiss deferred tax assets, as well as employee-equity tax benefits. These items materially affect comparisons of net income and effective tax rates.
Outlook, commentary, risks, and contingencies
- Outlook: The filing provides no specific revenue or earnings guidance and says it cannot reliably estimate COVID-19 effects on revenue in Q3 2021 and beyond. Management expects capital expenditures to exceed $300 million in both 2021 and 2022 and expects continued substantial R&D investment and rising expenses to support growth, innovation, manufacturing, and supply.
- Procedure and demand outlook: Further COVID-19 outbreaks, hospital capacity constraints, and postponed diagnosis or treatment could again affect procedures and system placements. Recovery varies by geography and procedure type; management cautions that deferred patients may not all return to surgery.
- Extended Use Program: Select instruments are being transitioned from 10 uses to 12–18 uses, with reduced pricing on certain instruments. Management expects the program and customer inventory adjustments to reduce instruments and accessories revenue per procedure over coming quarters. Based on 2019 procedure mix and volume, the changes would have reduced annual revenue by an estimated $150–$170 million.
- Supply chain: The company reports difficulty obtaining semiconductors and other materials, supply constraints, and inflationary cost pressure. Sole- and single-source suppliers and possible production delays could impair its ability to meet demand.
- Litigation: Product-liability cases remain pending; the company says a loss above recognized amounts is reasonably possible but cannot estimate the excess range. In a patent case, a June 2021 USITC initial determination found certain SureForm products infringed claims of two Ethicon patents; review was pending, and an unfavorable final ruling could restrict U.S. imports or require workarounds. The filing also describes multiple repair/service antitrust claims and says potential losses cannot be reasonably estimated for several matters.
- Other risks and unusual items: The filing highlights cybersecurity and information-system risks, regulatory approval and reimbursement uncertainty, competition, and foreign-market risks. The Swiss tax benefit and prior-year customer relief are notable non-recurring comparison items.
Important facts for investors to verify
- Whether procedure recovery and system demand persist after the unusually weak Q2 2020 comparison, including trends by region and procedure category.
- The realized revenue-per-procedure effect of Extended Use Instruments, price reductions, and customer inventory drawdowns.
- Whether semiconductor and other supply constraints affect production, shipments, costs, or customer service.
- The outcome and potential commercial consequences of the Ethicon USITC review and the pending antitrust and product-liability cases.
- How earnings and effective tax rates perform excluding the $66.4 million Swiss deferred-tax benefit and variable employee-equity tax benefits.